Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9437113 | 0.93 | KMT2A (0.38) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL30612351 | 0.89 | SLC6A2 (0.39) | — | |
| SCHEMBL1914312 | 0.77 | ALDH1A1 (0.36) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL1668263 | 0.77 | MEN1 (0.36) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL23782958 | 0.76 | SMN1; SMN2 (0.33) | KMT2AALDH1A1GAA | |
| SCHEMBL28207484 | 0.76 | CES2 (0.39) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL27817485 | 0.76 | MAPT (0.39) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL27776891 | 0.76 | MAPT (0.39) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL25326059 | 0.72 | IDO1 (0.44) | MEN1KMT2AMAPTALDH1A1CYP2C9 | |
| SCHEMBL1156420 | 0.72 | IDO1 (0.44) | MEN1KMT2AMAPTALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107056803-B | The method for synthesizing intermediate of prasugrel and preparation method thereof and synthesis prasugrel | 兰州大学 | 2019-06-11 | — | — | CN | claimed |
| EP-3475288-A1 | PROCESS FOR THE PREPARATION OF HIGH-PURITY PRASUGREL | Richter Gedeon Nyrt. (HU) | 2019-05-01 | — | — | EP | claimed |
| WO-2017221187-A1 | PROCESS FOR THE PREPARATION OF HIGH-PURITY PRASUGREL | RICHTER GEDEON NYRT. (HU) | 2017-12-28 | — | — | WO | claimed |
| WO-2014114964-A2 | IMPROVED PROCESS FOR THE PREPARATION OF PRASUGREL AND INTERMEDIATE THEREOF | EGIS PHARMACEUTICALS PUBLIC LIMITED COMPANY (HU) | 2014-07-31 | — | — | WO | claimed |
| CN-102190569-B | Method for preparing Prasugrel intermediate alpha-cyclopropylcarbonyl-2-fluorobenzyl bromide | ZHEJIANG HISOAR PHARMACEUTICAL CO LTD | 2014-07-02 | — | — | CN | claimed |
| CN-103819322-A | Preparation method of Prasugrel intermediate 2-halo-2-(2-fluorophenyl)-1-cyclopropylethanone | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2014-05-28 | — | — | CN | claimed |
| CN-102101827-B | Method for preparing Prasugrel intermediate alpha-cyclopropyl carbonyl-2-fluorobenzyl halide | SHANDONG XINHUA PHARMACEUTICAL | 2013-07-03 | — | — | CN | claimed |
| CN-101486635-B | Preparation of alpha-cyclopropyl carbonyl-2-benzyl-fluorobenzyl halogen | SHANGHAI INST PHARM INDUSTRY | 2012-10-10 | — | — | CN | claimed |
| EP-2499147-A2 | IMPROVED PROCESSES FOR PREPARING PRASUGREL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEROEOF | MSN Laboratories Limited (IN) | 2012-09-19 | — | — | EP | claimed |
| WO-2012052788-A1 | METHOD FOR PREPARING PHARMACEUTICALLY ACTIVE INGREDIENT AND INTERMEDIATES THEREOF | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG (HU) | 2012-04-26 | — | — | WO | claimed |
| CN-102311325-A | Method for preparing prasugrel intermediate cyclopropyl-2-fluorine benzyl ketone | SHANDONG XINHUA PHARMACEUTICAL | 2012-01-11 | — | — | CN | claimed |
| CN-102101827-A | Method for preparing Prasugrel intermediate alpha-cyclopropyl carbonyl-2-fluorobenzyl halide | SHANDONG XINHUA PHARMACEUTICAL | 2011-06-22 | — | — | CN | claimed |
| WO-2011042918-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PRASUGREL, ITS INTERMEDIATES AND PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-04-14 | — | — | WO | claimed |
| US-20110040093-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2011-02-17 | — | — | US | claimed |
| CN-101486635-A | Preparation of alpha-cyclopropyl carbonyl-2-benzyl-fluorobenzyl halogen | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-07-22 | — | — | CN | claimed |
| WO-2009066326-A2 | IMPROVED PROCESS FOR THE PREPARATION OF PRASUGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | WO | claimed |
| CN-107056803-B | The method for synthesizing intermediate of prasugrel and preparation method thereof and synthesis prasugrel | 兰州大学 | 2019-06-11 | — | — | CN | disclosed |
| CN-107056803-B | The method for synthesizing intermediate of prasugrel and preparation method thereof and synthesis prasugrel | 兰州大学 | 2019-06-11 | — | — | CN | disclosed |
| CN-1041730-C | Process for preparing hydrogenated pyridine derivatives | SANKYO CO (JP) | 1999-01-20 | — | — | CN | disclosed |
| CN-1074446-A | Hydroxypyridine Derivatives | SANKYO CO (JP) | 1993-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040093-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATE | CYP2F1, CYP4F3, CYP4F11 | MEN1 3196/4885KMT2A 3043/4885MAPT 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.